Exhibit 99.1 The Glimpse Group Reports Q3 Fiscal Year 2025 Financial Results Reaf irm Revenues and Second Consecutive Quarter of Positive Cash Flow NEW YORK, NY, May 15, 2025 - The Glimpse Group, Inc. ("Glimpse") (NASDAQ: VRAR; FSE: 9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, provided financial results for its third quarter fiscal year 2025, ended March 31, 2025 ("Q3 FY '2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 7683 SE 27 Street, Suite 481 Mercer I ...

Revenue Growth - Total revenue increased by $501,148, or 212%, from $236,677 for the three months ended March 31, 2024, to $737,825 for the same period in 2025, driven by a 38% increase in locations using services[99]. - Cloud video surveillance subscriptions increased by 79%, remote guarding increased by 164%, hardware sales increased by 241%, and installation labor sales increased by 397% compared to the same period in 2024[99]. Expenses - Cost of goods sold increased by $154,242, or 61%, from $253,232 for the three months ended March 31, 2024, to $407,473 for the same period in 2025[103]. - General and administrative expenses increased by 114% for the three months ended March 31, 2025, primarily due to a one-time bonus of $323,000 paid to employees[107]. - Research and development expenses increased by 71% for the three months ended March 31, 2025, with payroll increasing by $237,000 due to a one-time bonus[108]. Net Loss - Net loss for the three months ended March 31, 2025, was $2.5 million, compared to a net loss of $1.7 million for the same period in 2024, representing a 46% increase in loss[111]. Cash Position - Cash and cash equivalents at the end of the period were $6.845 million for the three months ended March 31, 2025, compared to $(1.028) million for the same period in 2024[115]. - Net cash provided by financing activities was $9.4 million for the three months ended March 31, 2025, compared to approximately $0 for the same period in 2024[120]. - As of March 31, 2025, the company had approximately $6.9 million in cash and $6.8 million in working capital, expecting current cash to fund operations through at least Q1 2026[126]. Future Outlook - The company anticipates entering additional markets in 2025 and 2026, focusing on expanding its customer base in the property management space[89]. - The company expects to incur additional losses for the foreseeable future as it continues to expand and develop new products and services[125]. - The company has an accumulated deficit of approximately $43.4 million as of March 31, 2025, and expects to continue incurring operating losses and negative cash flows for the foreseeable future[128]. - The Series 2 Purchase Agreement and Equity Purchase Agreement may provide necessary funding for the next 12 months, but their execution is subject to conditions beyond the company's control[127]. Financial Management - The company has a planning and budgeting process to monitor operating cash requirements, including capital expenditures, general and administrative costs, and public company operating costs[129]. - Contractual obligations primarily relate to operating lease obligations, capital lease obligations, and insurance obligations, which are generally terminable after a notice period[130]. - The company does not have any long-term debt or significant long-term liabilities as of the reporting period[131]. Regulatory Status - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of certain reporting exemptions[133]. - The company has elected to use an extended transition period for complying with new accounting standards, which may affect the comparability of its financial statements[134]. - The company is not required to provide certain disclosures related to executive compensation due to its status as an emerging growth company[138]. - The company evaluates its accounting estimates and assumptions on an ongoing basis, which may impact reported amounts of assets, liabilities, revenue, and expenses[140].

Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash. (May 15, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and busi ...

Exhibit 99.1 Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates FOR IMMEDIATE RELEASE DALLAS—(BUSINESS WIRE)— May 15, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter 2025 ended Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2528215 | | --- | --- | | (State or Ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-37673 WORKHORSE GROUP INC. (Exact name of registrant as specified in its charter) Nevada 26-1394771 (State or other ...

Exhibit 99.1 HeartCore Reports First Quarter 2025 Financial Results NEW YORK and TOKYO, May 15, 2025 (GLOBE NEWSWIRE) – HeartCore Enterprises, Inc. (Nasdaq: HTCR) ("HeartCore" or the "Company"), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenues were $3.6 million compared to $5.0 million in the same period last year. The decrease was primarily due to decreased on- p ...

Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 Exhibit 99.1 Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision OPGx-BEST1 on track for IND filing and initiation of Phase 1/2 trial with early data expected in Q1 2026 Leading healthcare investors provide funding to deliver on k ...

Exhibit 99.1 Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on track for IND filing and initiation of Phase 1/2 trial with early data expected in Q1 2026 Leading healthcare investors provide funding to deliver on k ...